Panacea Biotec Limited (PANACEABIO.NS)
NSE · INR · Healthcare · Biotechnology
₹319.25 (+4.07%) as of
Key statistics
- Market cap
- 19.51B
- EPS (TTM)
- -1.16
- Dividend yield
- 0.00%
- 52-week range
- 292.40 – 647.00
- Beta
- 0.25
- Revenue (TTM)
- 6.73B
- Profit margin
- -1.06%
- Volume
- 95.58k
About Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. The company operates through Vaccines and Pharmaceutical Formulations & Nutrition segments. Its product portfolio includes prescription products in various therapeutic areas, such as diabetes, gastro-intestinal care, nephrology, oncology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, and Mpox, etc. The company also offers health supplement products; and nutrition products under the ChilRun full, ChilRun 7+, and ChillRun No Sucrose brands. In addition, it engages in the real estate business. It exports its products to approximately 50 countries. It has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New Delhi, India
- Employees
- 2,102
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.